Description

The FDA has granted an orphan drug designation to sotigalimab (APX005M) as a potential therapeutic option for patients with soft tissue sarcoma, according to announcement from Apexigen Inc., the drug developer. A novel, humanized monoclonal antibody, sotigalimab was designed stimulate antitumor immune response and to target CD40, which is a key co-stimulatory receptor that serves to activate innate and adaptive immune systems. When sotigalimab binds to CD40 on antigen-presenting cells, it induces a multifaceted immune response that brings several components of the immune system together to attack the cancer.

Catalog No.

CSD68911

Host species

Humanized

Species reactivity

Human

Form

Liquid

Storage buffer

0.01M PBS, pH 7.4.

Concentration

2.54 mg/ml

Purity

>95%

Clonality

Monoclonal

Isotype

IgG1-Kappa

Applications

Research Grade Sotigalimab Biosimilar

Target

Tumor necrosis factor receptor superfamily member 5,B-cell surface antigen CD40,Bp50,CD40L receptor,TNFRSF5,CDw40,CD40

Purification

Protein A or G purified from cell culture supernatant.

Endotoxin level

Please contact with the lab for this information.

Expression system

Mammalian cells

Accession

P25942

Stability and Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles.Store at +4°C short term (1-2 weeks).Store at -20 °C 12 months. Store at -80°C long term.

Alternative Names

APX005M, APX-005, APX-005-M, APX-005M, CAS: 2305607-45-6

Note

For research use only. Not suitable for clinical or therapeutic use.